Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 170

1.

In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae.

Tóth Z, Forgács L, Locke JB, Kardos G, Nagy F, Kovács R, Szekely A, Borman AM, Majoros L.

J Antimicrob Chemother. 2019 Sep 20. pii: dkz390. doi: 10.1093/jac/dkz390. [Epub ahead of print]

PMID:
31539426
2.

Physiological and Transcriptional Responses of Candida parapsilosis to Exogenous Tyrosol.

Jakab Á, Tóth Z, Nagy F, Nemes D, Bácskay I, Kardos G, Emri T, Pócsi I, Majoros L, Kovács R.

Appl Environ Microbiol. 2019 Oct 1;85(20). pii: e01388-19. doi: 10.1128/AEM.01388-19. Print 2019 Oct 15.

PMID:
31399405
3.

Efficacy of humanized single large doses of caspofungin on the lethality and fungal tissue burden in a deeply neutropenic murine model against Candida albicans and Candida dubliniensis.

Prépost E, Tóth Z, Perlin DS, Gesztelyi R, Kardos G, Kovács R, Nagy F, Forgács L, Majoros L.

Infect Drug Resist. 2019 Jul 1;12:1805-1814. doi: 10.2147/IDR.S198764. eCollection 2019.

4.

A nonlinear time-series analysis approach to identify thresholds in associations between population antibiotic use and rates of resistance.

López-Lozano JM, Lawes T, Nebot C, Beyaert A, Bertrand X, Hocquet D, Aldeyab M, Scott M, Conlon-Bingham G, Farren D, Kardos G, Fésűs A, Rodríguez-Baño J, Retamar P, Gonzalo-Jiménez N, Gould IM; THRESHOLDS study group.

Nat Microbiol. 2019 Jul;4(7):1160-1172. doi: 10.1038/s41564-019-0410-0. Epub 2019 Apr 8.

PMID:
30962570
5.

Comparative analysis of human papillomavirus type 6 complete genomes originated from head and neck and anogenital disorders.

Szinai M, Nagy Z, Máté P, Kovács D, Laczkó L, Kardos G, Sápy T, Szűcs A, Szarka K.

Infect Genet Evol. 2019 Jul;71:140-150. doi: 10.1016/j.meegid.2019.03.019. Epub 2019 Mar 21.

PMID:
30905772
6.

Utilization of Vector Autoregressive and Linear Transfer Models to Follow Up the Antibiotic Resistance Spiral in Gram-negative Bacteria From Cephalosporin Consumption to Colistin Resistance.

Tóth H, Fésűs A, Kungler-Gorácz O, Balázs B, Majoros L, Szarka K, Kardos G.

Clin Infect Dis. 2019 Sep 27;69(8):1410-1421. doi: 10.1093/cid/ciy1086.

PMID:
30561543
7.

Comparison of Killing Activity of Micafungin Against Six Candida Species Isolated from Peritoneal and Pleural Cavities in RPMI-1640, 10 and 30% Serum.

Tóth Z, Kardos T, Kovács R, Kardos G, Nagy F, Prépost E, Barta Z, Takacs I, Majoros L.

Mycopathologia. 2018 Dec;183(6):905-912. doi: 10.1007/s11046-018-0302-5. Epub 2018 Oct 31.

PMID:
30382508
8.

Deletion of poly(ADP‑ribose) polymerase-1 changes the composition of the microbiome in the gut.

Vida A, Kardos G, Kovács T, Bodrogi BL, Bai P.

Mol Med Rep. 2018 Nov;18(5):4335-4341. doi: 10.3892/mmr.2018.9474. Epub 2018 Sep 10.

9.

Poor in vivo efficacy of caspofungin, micafungin and amphotericin B against wild-type Candida krusei clinical isolates does not correlate with in vitro susceptibility results.

Kardos T, Kovács R, Kardos G, Varga I, Bozó A, Tóth Z, Nagy F, Majoros L.

J Chemother. 2018 Jul;30(4):233-239. doi: 10.1080/1120009X.2018.1487150. Epub 2018 Jul 20.

PMID:
30025501
10.

Postantifungal effect of micafungin against Candida albicans, Candida dubliniensis and Candida africana in the presence and absence of serum.

Kardos T, Saleh Q, Kovács R, Gesztelyi R, Kardos G, Bozó A, Tóth Z, Majoros L.

New Microbiol. 2017 Oct;40(4):286-288. Epub 2017 Oct 10.

11.

Identification of WEE1 as a target to make AKT inhibition more effective in melanoma.

Kuzu OF, Gowda R, Sharma A, Noory MA, Kardos G, Madhunapantula SV, Drabick JJ, Robertson GP.

Cancer Biol Ther. 2018 Jan 2;19(1):53-62. doi: 10.1080/15384047.2017.1360446. Epub 2017 Nov 30.

12.

Improving pharmacological targeting of AKT in melanoma.

Kuzu OF, Gowda R, Sharma A, Noory MA, Dinavahi SS, Kardos G, Drabick JJ, Robertson GP.

Cancer Lett. 2017 Sep 28;404:29-36. doi: 10.1016/j.canlet.2017.07.001. Epub 2017 Jul 11.

PMID:
28705772
13.

Killing Activity of Micafungin Against Candida albicans, C. dubliniensis and Candida africana in the Presence of Human Serum.

Kovács R, Saleh Q, Bozó A, Tóth Z, Gesztelyi R, Kardos T, Kardos G, Takacs I, Majoros L.

Mycopathologia. 2017 Dec;182(11-12):979-987. doi: 10.1007/s11046-017-0178-9. Epub 2017 Jul 11.

PMID:
28699056
14.

Decreased Killing Activity of Micafungin Against Candida guilliermondii, Candida lusitaniae, and Candida kefyr in the Presence of Human Serum.

Saleh Q, Kovács R, Kardos G, Gesztelyi R, Kardos T, Bozó A, Majoros L.

Microb Drug Resist. 2017 Sep;23(6):764-770. doi: 10.1089/mdr.2016.0241. Epub 2017 Jan 10.

PMID:
28072553
15.

Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma.

Gowda R, Kardos G, Sharma A, Singh S, Robertson GP.

Mol Cancer Ther. 2017 Mar;16(3):440-452. doi: 10.1158/1535-7163.MCT-16-0285. Epub 2016 Dec 21.

16.

Expedient and Diastereodivergent Assembly of Terpenoid Decalin Subunits having Quaternary Stereocenters through Organocatalytic Robinson Annulation of Nazarov Reagent.

Berkes B, Ozsváth K, Molnár L, Gáti T, Holczbauer T, Kardos G, Soós T.

Chemistry. 2016 Dec 12;22(50):18101-18106. doi: 10.1002/chem.201604541. Epub 2016 Oct 31.

PMID:
27798820
17.

The in vitro and in vivo efficacy of fluconazole in combination with farnesol against Candida albicans isolates using a murine vulvovaginitis model.

Bozó A, Domán M, Majoros L, Kardos G, Varga I, Kovács R.

J Microbiol. 2016 Nov;54(11):753-760. Epub 2016 Oct 29.

PMID:
27796932
18.

Killing Rates of Caspofungin in 50 Percent Serum Correlate with Caspofungin Efficacy Against Candida albicans in a Neutropenic Murine Model.

Domán M, Kovács R, Kardos G, Gesztelyi R, Juhász B, Bozó A, Kardos T, Saleh Q, Majoros L.

Curr Drug Deliv. 2016;13(2):255-64.

PMID:
27146910
19.

Asymptomatic faecal carriage of ESBL producing enterobacteriaceae in Hungarian healthy individuals and in long-term care applicants: A shift towards CTX-M producers in the community.

Ebrahimi F, Mózes J, Mészáros J, Juhász Á, Majoros L, Szarka K, Kardos G.

Infect Dis (Lond). 2016 Jul;48(7):557-9. doi: 10.3109/23744235.2016.1155734. Epub 2016 Mar 16.

PMID:
26982242
20.

Effect of caspofungin and micafungin in combination with farnesol against Candida parapsilosis biofilms.

Kovács R, Bozó A, Gesztelyi R, Domán M, Kardos G, Nagy F, Tóth Z, Majoros L.

Int J Antimicrob Agents. 2016 Apr;47(4):304-10. doi: 10.1016/j.ijantimicag.2016.01.007. Epub 2016 Feb 17.

PMID:
26968084
21.

Comparison of rates of fecal colonization with extended-spectrum beta-lactamase-producing enterobacteria among patients in different wards, outpatients and medical students.

Ebrahimi F, Mózes J, Monostori J, Gorácz O, Fésűs A, Majoros L, Szarka K, Kardos G.

Microbiol Immunol. 2016 May;60(5):285-94. doi: 10.1111/1348-0421.12373.

22.

Dose escalation studies with caspofungin against Candida glabrata.

Domán M, Kovács R, Perlin DS, Kardos G, Gesztelyi R, Juhász B, Bozó A, Majoros L.

J Med Microbiol. 2015 Sep;64(9):998-1007. doi: 10.1099/jmm.0.000116. Epub 2015 Jun 30.

23.

Therapeutic interventions to disrupt the protein synthetic machinery in melanoma.

Kardos GR, Robertson GP.

Pigment Cell Melanoma Res. 2015 Sep;28(5):501-19. doi: 10.1111/pcmr.12391. Review.

24.

Disruption of Proline Synthesis in Melanoma Inhibits Protein Production Mediated by the GCN2 Pathway.

Kardos GR, Wastyk HC, Robertson GP.

Mol Cancer Res. 2015 Oct;13(10):1408-20. doi: 10.1158/1541-7786.MCR-15-0048. Epub 2015 Jun 16.

25.
26.

Effect of carbapenem consumption patterns on the molecular epidemiology and carbapenem resistance of Acinetobacter baumannii.

Mózes J, Ebrahimi F, Gorácz O, Miszti C, Kardos G.

J Med Microbiol. 2014 Dec;63(Pt 12):1654-62. doi: 10.1099/jmm.0.082818-0. Epub 2014 Sep 26.

PMID:
25261064
27.

[Special application of matrix-assisted laser desorption ionization time-of-flight mass spectrometry in clinical microbiological diagnostics].

Nagy E, Abrók M, Bartha N, Bereczki L, Juhász E, Kardos G, Kristóf K, Miszti C, Urbán E.

Orv Hetil. 2014 Sep 21;155(38):1495-503. doi: 10.1556/OH.2014.29985. Review. Hungarian.

PMID:
25217765
28.

Efficacy of single large doses of caspofungin in a neutropenic murine model against the "psilosis" group.

Berényi R, Kovács R, Domán M, Gesztelyi R, Kardos G, Juhász B, Perlin D, Majoros L.

New Microbiol. 2014 Jul;37(3):355-62. Epub 2014 Jul 1.

29.

Killing rates for caspofungin against Candida albicans after brief and continuous caspofungin exposure in the presence and absence of serum.

Kovács R, Gesztelyi R, Perlin DS, Kardos G, Domán M, Berényi R, Majoros L.

Mycopathologia. 2014 Oct;178(3-4):197-206. doi: 10.1007/s11046-014-9799-4. Epub 2014 Aug 15.

PMID:
25118874
30.

Growth inhibitory effects of large subunit ribosomal proteins in melanoma.

Kardos GR, Dai MS, Robertson GP.

Pigment Cell Melanoma Res. 2014 Sep;27(5):801-12. doi: 10.1111/pcmr.12259. Epub 2014 Jun 16.

31.

On the mechanism of bifunctional squaramide-catalyzed organocatalytic Michael addition: a protonated catalyst as an oxyanion hole.

Kótai B, Kardos G, Hamza A, Farkas V, Pápai I, Soós T.

Chemistry. 2014 May 5;20(19):5631-9. doi: 10.1002/chem.201304553. Epub 2014 Mar 27.

PMID:
24677388
32.

Killing rates exerted by caspofungin in 50 % serum and its correlation with in vivo efficacy in a neutropenic murine model against Candida krusei and Candida inconspicua.

Kovács R, Gesztelyi R, Berényi R, Domán M, Kardos G, Juhász B, Majoros L.

J Med Microbiol. 2014 Feb;63(Pt 2):186-94. doi: 10.1099/jmm.0.066381-0. Epub 2013 Nov 1.

PMID:
24184471
33.

A potential role of aminoglycoside resistance in endemic occurrence of Pseudomonas aeruginosa strains in lower airways of mechanically ventilated patients.

Mózes J, Szűcs I, Molnár D, Jakab P, Fatemeh E, Szilasi M, Majoros L, Orosi P, Kardos G.

Diagn Microbiol Infect Dis. 2014 Jan;78(1):79-84. doi: 10.1016/j.diagmicrobio.2013.09.015. Epub 2013 Oct 7.

PMID:
24183948
34.

Genomic differences in the background of different severity in juvenile-onset respiratory papillomatoses associated with human papillomavirus type 11.

Gáll T, Kis A, Tatár TZ, Kardos G, Gergely L, Szarka K.

Med Microbiol Immunol. 2013 Oct;202(5):353-63. doi: 10.1007/s00430-013-0297-y. Epub 2013 May 7.

PMID:
23649705
35.

Effect of 50% human serum on the killing activity of micafungin against eight Candida species using time-kill methodology.

Földi R, Szilágyi J, Kardos G, Berényi R, Kovács R, Majoros L.

Diagn Microbiol Infect Dis. 2012 Aug;73(4):338-42. doi: 10.1016/j.diagmicrobio.2012.05.011. Epub 2012 Jun 20.

PMID:
22726529
36.

Comparison of the kidney fungal burden in experimental disseminated candidiasis by species of the Candida parapsilosis complex treated with fluconazole, amphotericin B and caspofungin in a temporarily neutropenic murine model.

Szilágyi J, Földi R, Gesztelyi R, Bayegan S, Kardos G, Juhász B, Majoros L.

Chemotherapy. 2012;58(2):159-64. doi: 10.1159/000337088. Epub 2012 May 24.

PMID:
22626860
37.

Comparison of in vitro and vivo efficacy of caspofungin against Candida parapsilosis, C. orthopsilosis, C. metapsilosis and C. albicans.

Földi R, Kovács R, Gesztelyi R, Kardos G, Berényi R, Juhász B, Szilágyi J, Mózes J, Majoros L.

Mycopathologia. 2012 Oct;174(4):311-8. doi: 10.1007/s11046-012-9554-7. Epub 2012 May 8.

PMID:
22565489
38.

Effect of nikkomycin Z and 50% human serum on the killing activity of high-concentration caspofungin against Candida species using time-kill methodology.

Szilágyi J, Földi R, Bayegan S, Kardos G, Majoros L.

J Chemother. 2012 Feb;24(1):18-25. doi: 10.1179/1120009X12Z.0000000005.

PMID:
22546720
39.

Typical investigational medicinal products follow relatively uniform regulations in 10 European Clinical Research Infrastructures Network (ECRIN) countries.

Gluud C, Kubiak C, Whitfield K, Byrne J, Huemer KH, Thirstrup S, Libersa C, Barraud B, Grählert X, Dreier G, Geismann S, Kuchinke W, Temesvari Z, Blasko G, Kardos G, O'Brien T, Cooney M, Gaynor S, Schieppati A, de Andres F, Sanz N, Kreis G, Asker-Hagelberg C, Johansson H, Bourne S, Asghar A, Husson JM, Demotes-Mainard J.

Trials. 2012 Mar 27;13:27. doi: 10.1186/1745-6215-13-27.

40.

Comparison of diversity of torque teno virus 1 in different mucosal tissues and disorders.

Fehér E, Kardos G, Gáll T, Kis A, Gergely L, Szarka K.

Acta Microbiol Immunol Hung. 2011 Dec;58(4):319-37. doi: 10.1556/AMicr.58.2011.4.8.

PMID:
22207290
41.

From farm to fork follow-up of thermotolerant campylobacters throughout the broiler production chain and in human cases in a Hungarian county during a ten-months period.

Damjanova I, Jakab M, Farkas T, Mészáros J, Galántai Z, Turcsányi I, Bistyák A, Juhász A, Pászti J, Kiss I, Kardos G.

Int J Food Microbiol. 2011 Nov 1;150(2-3):95-102. doi: 10.1016/j.ijfoodmicro.2011.07.011. Epub 2011 Aug 4.

PMID:
21864930
42.

Efficacy of a single 6 mg/kg versus two 3 mg/kg caspofungin doses for treatment of disseminated candidiasis caused by Candida albicans in a neutropenic mouse model.

Bayegan S, Szilágyi J, Kemény-Beke Á, Földi R, Kardos G, Gesztelyi R, Juhasz B, Adnan A, Majoros L.

J Chemother. 2011 Apr;23(2):107-9.

PMID:
21571628
43.

Compassionate use of interventions: results of a European Clinical Research Infrastructures Network (ECRIN) survey of ten European countries.

Whitfield K, Huemer KH, Winter D, Thirstrup S, Libersa C, Barraud B, Kubiak C, Stankovski L, Grählert X, Dreier G, Geismann S, Kuchinke W, Strenge-Hesse A, Temesvari Z, Blasko G, Kardos G, O'Brien T, Cooney M, Gaynor S, Schieppati A, Serrano M, de Andres F, Sanz N, Hernández R, Kreis G, Asker-Hagelberg C, Johansson H, Asghar A, Husson JM, Demotes J, Gluud C.

Trials. 2010 Nov 12;11:104. doi: 10.1186/1745-6215-11-104.

44.

In vivo studies with a Candida tropicalis isolate exhibiting paradoxical growth in vitro in the presence of high concentration of caspofungin.

Bayegan S, Majoros L, Kardos G, Kemény-Beke A, Miszti C, Kovacs R, Gesztelyi R.

J Microbiol. 2010 Apr;48(2):170-3. doi: 10.1007/s12275-010-9221-y. Epub 2010 May 1.

PMID:
20437148
45.

Harmonisation of ethics committees' practice in 10 European countries.

Hernandez R, Cooney M, Dualé C, Gálvez M, Gaynor S, Kardos G, Kubiak C, Mihaylov S, Pleiner J, Ruberto G, Sanz N, Skoog M, Souri P, Stiller CO, Strenge-Hesse A, Vas A, Winter D, Carné X.

J Med Ethics. 2009 Nov;35(11):696-700. doi: 10.1136/jme.2009.030551.

PMID:
19880708
46.

Common definition for categories of clinical research: a prerequisite for a survey on regulatory requirements by the European Clinical Research Infrastructures Network (ECRIN).

Kubiak C, de Andres-Trelles F, Kuchinke W, Huemer KH, Thirstrup S, Whitfield K, Libersa C, Barraud B, Grählert X, Dreier G, Grychtol R, Temesvari Z, Blasko G, Kardos G, O'Brien T, Cooney M, Gaynor S, Schieppati A, Sanz N, Hernandez R, Asker-Hagelberg C, Johansson H, Bourne S, Byrne J, Asghar A, Husson JM, Gluud C, Demotes-Mainard J.

Trials. 2009 Oct 16;10:95. doi: 10.1186/1745-6215-10-95.

47.

In vitro efficacy of amphotericin B, 5-fluorocytosine, fluconazole, voriconazole and posaconazole against Candida dubliniensis isolates using time-kill methodology.

Szabo Z, Borbely A, Kardos G, Somogyvari F, Kemény-Beke A, Asztalos L, Rozgonyi F, Majoros L.

Mycoses. 2010 May;53(3):196-9. doi: 10.1111/j.1439-0507.2009.01705.x. Epub 2009 Sep 16.

PMID:
19761489
48.

Virulence genes and molecular typing of different groups of Escherichia coli O157 strains in cattle.

Tóth I, Schmidt H, Kardos G, Lancz Z, Creuzburg K, Damjanova I, Pászti J, Beutin L, Nagy B.

Appl Environ Microbiol. 2009 Oct;75(19):6282-91. doi: 10.1128/AEM.00873-09. Epub 2009 Aug 14.

49.

Clinical research in Hungary. Infrastructure, organisation, legislation and framework. The situation in 2008.

Blaskó G, Kardos G.

Therapie. 2009 Jan-Feb;64(1):33-45. doi: 10.2515/therapie/2009003. Epub 2009 May 26. Review.

PMID:
19463251
50.

In vitro efficacy of 5 antifungal agents against Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis as determined by time-kill methodology.

Szabó Z, Szilágyi J, Tavanti A, Kardos G, Rozgonyi F, Bayegan S, Majoros L.

Diagn Microbiol Infect Dis. 2009 Jul;64(3):283-8. doi: 10.1016/j.diagmicrobio.2009.03.011. Epub 2009 Apr 25.

PMID:
19394787

Supplemental Content

Loading ...
Support Center